New cocktail of cancer drugs shows promise for tough head and neck tumors
NCT ID NCT05249426
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that didn't respond to previous treatments. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth signals, and one that cuts off the tumor's blood supply. The goal is to see if these combinations work better together, with regular checkups to monitor safety and tumor size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
"Prof. Dr. Alexandru Trestioreanu" Oncology Institut
Bucharest, 022328, Romania
-
ARENSIA Exploratory Medicine
Chisinau, MD-2025, Moldova
-
ARKE SMO S.A. de C.V
Mexico City, 06700, Mexico
-
CTR Georges-François Leclerc
Dijon, 21079, France
-
CTR Leon Berard
Lyon, 69373, France
-
FAICIC S de RL de C.V.
Veracruz, 91900, Mexico
-
HOP Civil
Strasbourg, 67091, France
-
HOP Timone
Marseille, 13385, France
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Duran i Reynals
L'Hospitalet de Llobregat, 08907, Spain
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
INS Claudius Regaud IUCT-Oncopole
Toulouse, 31059, France
-
INS Curie
Paris, 75248, France
-
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Cluj-Napoca, 400015, Romania
-
Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V.
Zapopan, 45070, Mexico
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
King Chulalongkorn Memorial Hospital
Bangkok, 10330, Thailand
-
King's College Hospital
London, SE5 9RS, United Kingdom
-
Mandziuk Slawomir Specialist Medical Practice
Lublin, 20-093, Poland
-
Sarawak General Hospital
Kuching, Sarawak, 93586, Malaysia
-
Songklanagarind Hospital
Songkhla, 90110, Thailand
-
The Royal Marsden Hospital, Chelsea
London, SW3 6JJ, United Kingdom
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
Conditions
Explore the condition pages connected to this study.